CLSD Clearside Biomedical Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CLSD

Price (delayed)

$1.31

Market cap

$97.88M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.53

Enterprise value

$111.97M

Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside's proprietary SCS ...

Highlights
CLSD's gross margin is up by 28% from the previous quarter and by 13% YoY
The company's net income rose by 13% QoQ
CLSD's quick ratio is down by 49% YoY and by 16% from the previous quarter
CLSD's equity is down by 24% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://clearsidebio.com
Peers: OMER OMGA

Key stats

What are the main financial stats of CLSD
Market
Shares outstanding
74.72M
Market cap
$97.88M
Enterprise value
$111.97M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
9.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.61
Earnings
Revenue
$8.23M
EBIT
-$32.49M
EBITDA
-$32.42M
Free cash flow
-$19.91M
Per share
EPS
-$0.53
Free cash flow per share
-$0.32
Book value per share
-$0.25
Revenue per share
$0.13
TBVPS
$0.55
Balance sheet
Total assets
$34.02M
Total liabilities
$49.93M
Debt
$43M
Equity
-$15.91M
Working capital
$23.31M
Liquidity
Debt to equity
-2.7
Current ratio
4.42
Quick ratio
4.27
Net debt/EBITDA
-0.43
Margins
EBITDA margin
-394.1%
Gross margin
95.7%
Net margin
-394.9%
Operating margin
-302%
Efficiency
Return on assets
-85.3%
Return on equity
N/A
Return on invested capital
-82.9%
Return on capital employed
-119.4%
Return on sales
-394.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CLSD stock price

How has the Clearside Biomedical stock price performed over time
Intraday
-0.76%
1 week
-2.24%
1 month
-8.39%
1 year
31.63%
YTD
11.97%
QTD
-14.38%

Financial performance

How have Clearside Biomedical's revenue and profit performed over time
Revenue
$8.23M
Gross profit
$7.87M
Operating income
-$24.84M
Net income
-$32.49M
Gross margin
95.7%
Net margin
-394.9%
The operating margin has soared by 87% YoY and by 78% from the previous quarter
CLSD's net margin has surged by 84% year-on-year and by 77% since the previous quarter
CLSD's gross margin is up by 28% from the previous quarter and by 13% YoY
The operating income has grown by 18% YoY and by 17% from the previous quarter

Growth

What is Clearside Biomedical's growth rate over time

Valuation

What is Clearside Biomedical stock price valuation
P/E
N/A
P/B
N/A
P/S
9.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.61
The EPS has grown by 13% since the previous quarter and by 3.6% year-on-year
CLSD's equity is down by 24% since the previous quarter
The P/S is 79% below the 5-year quarterly average of 47.3 and 72% below the last 4 quarters average of 35.1

Efficiency

How efficient is Clearside Biomedical business performance
The return on sales has surged by 84% year-on-year and by 77% since the previous quarter
Clearside Biomedical's return on invested capital has surged by 65% YoY and by 18% QoQ
The company's return on assets fell by 13% YoY but it rose by 3.1% QoQ

Dividends

What is CLSD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLSD.

Financial health

How did Clearside Biomedical financials performed over time
The company's total assets is 32% lower than its total liabilities
CLSD's quick ratio is down by 49% YoY and by 16% from the previous quarter
The current ratio has contracted by 48% YoY and by 16% from the previous quarter
The debt to equity has plunged by 181% YoY but it has grown by 17% from the previous quarter
CLSD's equity is down by 24% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.